Wednesday, 20 November 2019

Thyas signs a licensing agreement with iPS-AJ

18 January 2019 | News

Thyas is a start-up biotechnology company from Center for iPS cell Research and Application, Kyoto University, Japan, and supported by Kyoto University Innovation Capital Co. Ltd., a wholly owned investment firm of the university.

Thyas has signed a licensing agreement with iPS Academia Japan, Inc. (iPS-AJ), a technology licensing organization of induced pluripotent stem (iPS) cell related-patents from Kyoto University. Under the agreement, Thyas obtains exclusive rights on patents related to production and use of iPS cell-derived T cells, and non-exclusive rights on the patents related to iPS cell generation, for development and commercialization of autologous immunotherapy of cancers and infectious diseases. Thyas will pay ongoing licensing fees to iPS-AJ. Financial terms of the agreement have not been disclosed.

The method to generate highly antigen specific iPSC-derived killer T cells is established by Dr. Shin Kaneko, an associate professor and a leading scientist of immunotherapy using iPSC-derived killer T cells, in Center for iPS cell Research and Application, Kyoto University.  The iPSC technology allows Thyas to stably supply a large quantity of tumor-specific or virus-specific T cells that have high proliferative capacity and potent killing activity.  As of today, no other method produces highly antigen specific iPSC-derived killer T cells.

Novel immunotherapies have demonstrated significant benefits to cancer patients, however, the use of those is limited due to severe adverse events and therapy resistance. Thyas iPS-derived T cell products are expected to be safe and highly effective to many patients with cancers and infectious diseases. Therefore, the approach has a great clinical advantage.

Thyas is a start-up biotechnology company from Center for iPS cell Research and Application, Kyoto University, Japan, and supported by Kyoto University Innovation Capital Co. Ltd., a wholly owned investment firm of the university. The company is developing autologous immunotherapy with iPSC-derived killer T cells to cure patients suffering deadly diseases. Its key technologies are established by Dr. Shin Kaneko, Center for iPS cell Research and Application, Kyoto University. 

iPS-AJ is an approved TLO (technology licensing organization) (since 2016) which was established in 2008 to widely promote the use of iPS cell-related patents based on the research results by Prof. Shinya Yamanaka and his colleagues and iPS-AJ grants licenses regarding iPS cell-related patents with the aim of benefiting the health and welfare of human beings.

Sign up for the editor pick and get articles like this delivered right to your inbox.

Editors Pick
+Country Code-Phone Number(xxx-xxxxxxx)


Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account